Meeting
2022 ASCO Genitourinary Cancers Symposium
A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naïve prostate cancer (mHNPC): ZZFIRST.
Authors
Joaquin Mateo
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain
Joaquin Mateo , Ángel Borque , Daniel E. Castellano , Elena Castro , Miguel Angel A. Climent Duran , Albert Font , David Lorente , Begona Mellado , Alejo Rodriguez-Vida , Merce Cuadras , Jacques Planas , Irene Casanova Salas , Sarai Cordoba , Lucila Gonzalez , Marta Martínez de Falcon , Melissa Fernández , Miguel Sampayo-Cordero , Andrea Malfettone , Raquel Perez-Lopez , Joan Carles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04332744
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS209)
DOI
10.1200/JCO.2022.40.6_suppl.TPS209
Abstract #
TPS209
Poster Bd #
R6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay
Poster
2023 ASCO Annual Meeting
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2021 Genitourinary Cancers Symposium
Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2019 Genitourinary Cancers Symposium
Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue.
First Author: Adam Sharp